Drugs in Dev. Oncology
Phase II/ Phase III
Ireland 
Lead Product(s) : Mocravimod
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KRP203 (mocravimod) is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. This drug is in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmune indications such as AML patients undergoing HCT.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 23, 2023
Lead Product(s) : Mocravimod
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mocravimod
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Global Phase 2b/3 trial (MO-TRANS) assessing the efficacy and safety of mocravimod, a novel S1P receptor modulator, as an adjunctive and maintenance therapy in AML patients undergoing allogeneic HSCT, planned to start in H2 2022.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Mocravimod
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Asparaginase Erwinia Chrysanthemi
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Bionical Emas
Deal Size : Inapplicable
Deal Type : Inapplicable
Bionical Emas Launches Expanded Access Program for JZP458 - A Recombinant Erwinia Asparaginase
Details : JZP458 is launched for the treatment of adult and pediatric patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) following hypersensitivity or silent inactivation to E. coli-derived asparaginases.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
May 10, 2021
Lead Product(s) : Recombinant Asparaginase Erwinia Chrysanthemi
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Bionical Emas
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JZP-458
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Children's Oncology Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JZP-458 is a Enzyme drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
October 30, 2019
Lead Product(s) : JZP-458
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Children's Oncology Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Valrubicin
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Valrubicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma in Situ.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 16, 2011
Lead Product(s) : Valrubicin
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
